“[…] “The results of Tolmeijer et al. show that detection of ctDNA during treatment is promising, as it allows early determination of treatment response and can potentially help guide treatment management of patients with mCRPC.”
BUFFALO, NY – July 17, 2024 – A new editorial article has been published in Oncotarget Volume 15 July 2, 2024, titled “Use of early measurements of circulating tumor DNA during treatment as an assessment of response in metastatic castration-resistant prostate cancer” . “
In this new editorial, researchers SH Tolmeijer, E. Boerrigter, NP Van Erp and Niven Mehra from Radboud University Medical Center discuss metastatic castration-resistant prostate cancer (mCRPC). mCRPC is deadly, but the number of life-prolonging systemic treatments available for mCRPC has increased over the years. Real-world data suggest that the most common first-line treatment for mCRPC was androgen receptor pathway inhibitor (ARPI) therapy, namely enzalutamide or abiraterone, although increasingly patients are now receiving ARPI and/or docetaxel for hormone-sensitive prostate cancer (HSPC).
Recent clinical trial data suggest a potential benefit of adding poly-ADP ribose polymerase inhibitors (PARPi) or lutetium-117 prostate-specific membrane antigen (LuPSMA) to first-line ARPI treatment of mCRPC in a subset of patients. Given that these different drug classes are associated with different toxicity profiles and significant costs, it is very important to identify patients who benefit durably from ARPI monotherapy and those who could potentially benefit from treatment intensification or switching.
“Research by Tolmeijer et al. 2023, published in Clinical Cancer Research [13]suggests that detection of circulating tumor DNA (ctDNA) at baseline and 4 weeks after treatment initiation can predict durability of response to first-line ARPI.
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28599
Correspondence to: Niven Mehra
/Public dissemination. This content from the original organization/authors may be of a point-in-time nature and edited for clarity, style, and length. Mirage.News takes no institutional position or bias, and all views, positions, and conclusions expressed herein are solely those of the author(s). See the full story here.